Royalty Pharma PLC
NASDAQ:RPRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Royalty Pharma PLC
NASDAQ:RPRX
|
US |
|
A
|
Acea SpA
XMUN:DCA
|
IT |
|
J
|
Johnson Matthey PLC
DUS:JMT2
|
UK |
|
VGP NV
XBRU:VGP
|
BE |
|
G
|
GeoCrystal Ltd
ASX:GDC
|
AU |
|
H
|
Hera SpA
XBER:HE9
|
IT |
|
S
|
Schloss Wachenheim AG
XMUN:SWA
|
DE |
|
A
|
Abbvie Inc
BMV:ABBV
|
US |
|
Amada Co Ltd
OTC:AMDWF
|
JP |
|
1
|
11 Bit Studios SA
XMUN:11C
|
PL |
|
Rexel SA
OTC:RXLSF
|
FR |
|
Pacific Ridge Exploration Ltd
OTC:PEXZD
|
CA |
|
U
|
Ubisoft Entertainment SA
XMUN:UEN
|
FR |
|
Atos SE
OTC:AEXAD
|
FR |
|
Gemfields Group Ltd
F:5PH
|
GG |
|
A
|
Atlantic Sapphire ASA
XMUN:4AS
|
NO |
|
V
|
Vinhomes JSC
VN:VHM
|
VN |
|
B
|
BCPG PCL
SET:BCPG
|
TH |
|
S
|
Sakata Inx Corp
TSE:4633
|
JP |
|
I
|
Imax Corp
SWB:IMA
|
CA |
Wall St Price Targets
RPRX Price Targets Summary
Royalty Pharma PLC
According to Wall Street analysts, the average 1-year price target for RPRX is 58.38 USD with a low forecast of 46.46 USD and a high forecast of 69.3 USD.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is RPRX's stock price target?
Price Target
58.38
USD
According to Wall Street analysts, the average 1-year price target for RPRX is 58.38 USD with a low forecast of 46.46 USD and a high forecast of 69.3 USD.
What is the Revenue forecast for Royalty Pharma PLC?
Projected CAGR
18%
Over the last 7 years, the compound annual growth rate for Revenue has been 4%. The projected CAGR for the next 3 years is 18%.
What is the Operating Income forecast for Royalty Pharma PLC?
Projected CAGR
12%
Over the last 7 years, the compound annual growth rate for Operating Income has been 2%. The projected CAGR for the next 8 years is 12%.
What is the Pre-Tax Income forecast for Royalty Pharma PLC?
Projected CAGR
37%
Over the last 7 years, the compound annual growth rate for Pre-Tax Income has been -2%. The projected CAGR for the next 3 years is 37%.
What is the Net Income forecast for Royalty Pharma PLC?
Projected CAGR
63%
Over the last 7 years, the compound annual growth rate for Net Income has been -8%. The projected CAGR for the next 3 years is 63%.
